Astrazeneca Phar

{
  "main_header": {
    "sid": 777011,
    "name": "Astrazeneca Phar",
    "stock_name": "Astrazeneca Phar",
    "full_name": "Astrazeneca Pharma India Ltd",
    "name_url": "stocks-analysis/astrazeneca-phar",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "8,092.00",
    "chg": -145.4,
    "chgp": "-1.77%",
    "dir": -1,
    "prev_price": "8,237.40",
    "mcapval": "20,438.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 506820,
    "symbol": "ASTRAZEN",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE203A01020",
    "curr_date": "Jul 16, 03:30 PM",
    "curr_time": "17:23 PM",
    "last_traded_at": "Jul 16, 03:30 PM IST",
    "bse_nse_vol": "6.47 k",
    "exc_status": "Active",
    "traded_date": "Jul 16, 2026",
    "traded_date_str": "2026 07 16",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astrazeneca-phar-777011-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-4097003",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/AstrazenecaPhar_mojoScore_4097003.png",
        "date": "2026-07-11 10:10:18",
        "description": "Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 11 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-4078812",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstrazenecaPhar_mojoScore_4078812.png",
        "date": "2026-06-30 10:10:31",
        "description": "Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Astrazeneca Pharma India Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrazeneca-pharma-india-ltd-faces-bearish-momentum-amid-technical-downgrade-4077911",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstrazenecaPhar_technicaldot_4077911.png",
        "date": "2026-06-30 08:05:54",
        "description": "Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and momentum oscillators, suggests increasing downside pressure amid a challenging market environment for the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-4063132",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstrazenecaPhar_mojoScore_4063132.png",
        "date": "2026-06-19 10:10:57",
        "description": "Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-4037395",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstrazenecaPhar_mojoScore_4037395.png",
        "date": "2026-06-08 10:10:23",
        "description": "Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Astrazeneca Pharma India Ltd Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrazeneca-pharma-india-ltd-technical-momentum-shifts-amid-mixed-signals-4029611",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AstrazenecaPhar_technicaldot_4029611.png",
        "date": "2026-06-02 08:06:34",
        "description": "Astrazeneca Pharma India Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.61%, the stock’s technical indicators present a complex picture, reflecting both bullish and bearish signals across weekly and monthly timeframes."
      },
      {
        "title": "Astrazeneca Pharma India Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/astrazeneca-pharma-india-ltd-is-rated-sell-4017891",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AstrazenecaPhar_mojoScore_4017891.png",
        "date": "2026-05-28 10:10:44",
        "description": "Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "Are Astrazeneca Pharma India Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-astrazeneca-pharma-india-ltd-latest-results-good-or-bad-4017354",
        "imagepath": "",
        "date": "2026-05-27 19:44:56",
        "description": "AstraZeneca Pharma India Ltd's latest financial results for Q4 FY26 present a mixed picture, highlighting significant operational challenges alongside notable revenue growth. The company reported net sales of ₹578.61 crores, reflecting a year-on-year growth of 20.42% compared to ₹480.48 crores in Q4 FY25. However, this figure represents a sequential decline of 5.39% from ₹611.57 crores in Q3 FY26, indicating potential seasonal weaknesses or market share challenges.\n\nIn terms of profitability, AstraZeneca faced considerable pressure. The net profit for the quarter was ₹44.88 crores, which marks a decline of 22.96% quarter-on-quarter and a 22.95% drop year-on-year from ₹58.25 crores in the same quarter last year. This decline in profit occurred despite the strong revenue growth, suggesting that the company is experiencing significant margin compression. The operating margin fell sharply to 10.53%, down from 1..."
      },
      {
        "title": "AstraZeneca Pharma Q4 FY26: Margin Pressure Clouds Strong Revenue Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/astrazeneca-pharma-q4-fy26-margin-pressure-clouds-strong-revenue-growth-4017035",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AstrazenecaPhar_quaterlyResult_4017035.png",
        "date": "2026-05-27 11:50:20",
        "description": "AstraZeneca Pharma India Ltd. reported a challenging quarter for Q4 FY26 (January-March 2026), with net profit declining to ₹44.88 crores, down 22.96% quarter-on-quarter (QoQ) from ₹58.25 crores in Q3 FY26, despite posting robust revenue growth of 20.42% year-on-year (YoY). The stock reacted sharply to the mixed results, declining 5.17% to close at ₹8,520.00 on May 27, 2026, as investors grappled with deteriorating margins and profitability concerns despite the company's strong topline momentum."
      }
    ],
    "total": 375,
    "sid": "777011",
    "stock_news_url": "https://www.marketsmojo.com/news/astrazeneca-pharma-india-777011"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel (SMP)",
      "datetime": "06-Jul-2026",
      "details": "Please find the enclosed intimation of the Company as per the captioned subject for your reference.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel",
      "datetime": "16-Jun-2026",
      "details": "Please find the enclosed letter of the Company as per the captioned subject for reference.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "15-Jun-2026",
      "details": "Please find the enclosed intimation of the Company as per the captioned subject for your reference.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Astrazeneca Pharma India Ltd has declared <strong>1600%</strong> dividend, ex-date: 18 Jul 25",
          "dt": "2025-07-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Astrazeneca Pharma India Ltd has announced <strong>2:10</strong> stock split, ex-date: 15 Jun 06",
          "dt": "2006-06-15",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Astrazeneca Pharma India Ltd is Rated Sell

2026-07-11 10:10:18

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 11 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-06-30 10:10:31

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Astrazeneca Pharma India Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-06-30 08:05:54

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and momentum oscillators, suggests increasing downside pressure amid a challenging market environment for the Pharmaceuticals & Biotechnology sector.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-06-19 10:10:57

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-06-08 10:10:23

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Astrazeneca Pharma India Ltd Technical Momentum Shifts Amid Mixed Signals

2026-06-02 08:06:34

Astrazeneca Pharma India Ltd has experienced a nuanced shift in its technical momentum, with recent data revealing a transition from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.61%, the stock’s technical indicators present a complex picture, reflecting both bullish and bearish signals across weekly and monthly timeframes.

Read full news article

Astrazeneca Pharma India Ltd is Rated Sell

2026-05-28 10:10:44

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Read full news article

Are Astrazeneca Pharma India Ltd latest results good or bad?

2026-05-27 19:44:56

AstraZeneca Pharma India Ltd's latest financial results for Q4 FY26 present a mixed picture, highlighting significant operational challenges alongside notable revenue growth. The company reported net sales of ₹578.61 crores, reflecting a year-on-year growth of 20.42% compared to ₹480.48 crores in Q4 FY25. However, this figure represents a sequential decline of 5.39% from ₹611.57 crores in Q3 FY26, indicating potential seasonal weaknesses or market share challenges. In terms of profitability, AstraZeneca faced considerable pressure. The net profit for the quarter was ₹44.88 crores, which marks a decline of 22.96% quarter-on-quarter and a 22.95% drop year-on-year from ₹58.25 crores in the same quarter last year. This decline in profit occurred despite the strong revenue growth, suggesting that the company is experiencing significant margin compression. The operating margin fell sharply to 10.53%, down from 1...

Read full news article

AstraZeneca Pharma Q4 FY26: Margin Pressure Clouds Strong Revenue Growth

2026-05-27 11:50:20

AstraZeneca Pharma India Ltd. reported a challenging quarter for Q4 FY26 (January-March 2026), with net profit declining to ₹44.88 crores, down 22.96% quarter-on-quarter (QoQ) from ₹58.25 crores in Q3 FY26, despite posting robust revenue growth of 20.42% year-on-year (YoY). The stock reacted sharply to the mixed results, declining 5.17% to close at ₹8,520.00 on May 27, 2026, as investors grappled with deteriorating margins and profitability concerns despite the company's strong topline momentum.

Read full news article

View All News